DNAP!!!!! Das Warten hat ein Ende - 500 Beiträge pro Seite

[FCHennes]

Wahnsinn!!!!

Die Rakete wird zünden mit dem Deal mit Biofrontera!!!
Nach 4 Jahren "ein Etappenziel erreicht"

In Amerika brodelt die Gerüchteküche und die nächsten Raketennews werden kommen!!

Ich würd mal schnell reingehen.

[4ju1]

Dann tu`s doch...

[cineman]

sag mal was meinst dumit deal von Biofrontera????
glaube du lebst wohl 6 monate im rückstand!!!

cineman

[FCHennes]

@cineman

Wichig ist es, manchmal im richtigen Augenblick daran zu erinnern!

DNAPrint buying stake in drugmaker

BY MARGARET ANN MIILLE



SARASOTA -- DNAPrint Genomics Inc. is tapping into a drug development pipeline by becoming the majority owner of a German pharmaceutical company.

DNAPrint announced this week that it has agreed to acquire 51.77 percent of Biofrontera AG, a company based in Keverkusen and Heidelberg. The money for the deal will come from the Dutchess Private Equity Fund, which will buy up to $35 million of DNAPrint`s stock over two years.

DNAPrint has agreed to invest about $25 million during the same length of time in Biofrontera shares, representing a 51.77 percent equity interest.

" This is what I have been waiting for for the past four years, to reach this stage of legitimacy," said Tony Frudakis, the company`s founder and chief science officer. " From the very beginning, we`ve wanted to become a drug company, not just a data company that makes neat genetic tests."

DNAPrint, which has developed genetic tests that genealogists and forensic experts use to determine a person`s racial mix, said the Biofrontera deal will give DNAPrint access to drugs already under development and allow the two companies to share technology.

The focus will be on " theranostics," which blend genomics tests with drugs to yield the best results in specific groups of people.

Biofrontera`s lead candidate for development is a drug called " BF-Derm1," which is in clinical trials for treating chronic itching and scratching. Frudakis said that drug so far has shown a 40 percent improvement when compared with a placebo in reducing clinical symptoms in all patients.

Biofrontera, which focuses on developing treatments for inflammation and central nervous system diseases, also is in the early stages of developing a drug to treat and prevent migraines.

DNAPrint said it will continue selling its ancestry tests, called DNAWitness when marketed to the forensics market and ANCESTRYbyDNA2.5 when sold to the public.

But it intends to wrap up its research and market diagnostic tests for determining what existing drugs work the best for certain patients.

" Most of our efforts in the future will focus on developing our pipeline of new drugs," Frudakis said.

The two companies plan to eventually seek out a manufacturer when their drugs reach the production stage.

DNAPrint said the agreement with Dutchess, a limited partnership based in Boston, was arranged by Athena Capital Partners Inc., a private merchant bank in Tampa.

Frudakis Continued
1 | 2 | Next > >
DNAPrint buying stake in drugmaker

BY MARGARET ANN MIILLE



(Page 2)
. . . Frudakis said the acquisition eventually should boost investor confidence and buying activity in his company`s over-the-counter stock.

At the close of trading Thursday, shares were selling for 1.9 cents, down from 2.2 cents the previous day.

" Investors value data companies, basic science companies, much lower than they do pharmaceutical companies," Frudakis said. " The money in this business is in selling medicine."

http://www.heraldtribune.com/apps/pbcs.dll/article?AID=/2004…

[brokersvenja007]

binb ganz eurer meinung,...bin gestern rein...vielleicht 0,001-0,002 € zu früh, aber das spielt keine rolle,...

die geschichte hört sich gut an, aktie seit jahren auf so niedrigen niveau, da man immer auf solche nachrichten gewartet hat,....die letzten jahre wurde damit gegeizt.

jetzt hat man etwas vorzeigbares und beginnt bald mit der produktion...und dann ist der aktuelle kurs mehr als hinfällig...

alte höchststände 0,15 sind dann schnell wieder zu erreichen...und das sind dann auch immerhin

1000% wenn ich mich nciht ganz verrechnet habe!!

grüße
svenja

[Leo02]

Noch mal - wenn der RS kommt, ist jeder Kauf auf jetzigem Niveau ein Fehlkauf !!!!!

[FCHennes]

Der Leo will doch auch noch günstig rein...

[ebbe04]

richtig, fc Hennes,
glaub unser Leo spekuliert auf unsere Aktien!!!
leider ist bald der Zug abgefahren und dann lesen wir
nix mehr hier von Leo.

Der bevorstehende RS und eine neue News wird bald dafür
Sorge tragen, dass man sich bei DNAP nicht mehr mit sovielen "nullen" beschäftigen muss.

[Michiko]

Sagt mal,

was redet ihr denn hier für ein seltsames Zeugs?

Der Biofrontera-Deal ist geplatzt; nachzulesen im Filing.
Und nach einem RS geht es erfahrungsgemäß erstmal runter wegen der drohenden Dilution.

Die einzige Hoffnung sind gigantische News, sonst aber auch nix!

[FCHennes]

Der RS ist doch schon superlange bekannt und es ging doch schon runter. Wartet mal ab. Wenn der erfolgt ist, dann geht es nämlich spätestens nach oben.

@ebbe04
Schön, das auch der erste Schalker auf DNAP aufwerksam wird...

[FCHennes]

Oha,

da ging es gestern abba ganz schön runter. Der RS sollte jetzt wirklich eingepreist sein!!Und: So konnte man weiterhin billig einsammeln, was ich ehrlich gesagt nicht mehr für möglich gehalten habe. Die Story von DNAP stimmt und da wird noch Großes kommen.

[Leo02]

wann ???? 2009 ?????

[ebbe04]

Hennes,
DAS IST ABSOLUT RICHTIG!!!

Denke manchmal einige Leute sollten sich besser nicht mit
Aktien beschäftigen,wenn sie nicht voll im Thema stehen.

Naja, denke wir werden bald die Gläser heben

[Michiko]

Mannomann, primitiver geht`s kaum:

Username: ebbe04
Registriert seit: 15.06.2005
User ist momentan: Offline
Letztes Login: 16.06.2005 09:54:24
Threads: 0
Postings: 2 [ Durchschnittlich 2,0171 Beiträge/Tag ]
Postings der letzten 30 Tage anzeigen
Interessen: keine Angaben


Hennes, haste Dir rechtzeitig zur Eröffnung dieses absolut supernotwendigen Threads zur Verstärkung noch ne Lobhudel-Id zugelegt.
Ich seh ja ein, dass Du jetzt, nachdem Du gekauft hast, gerne ein bißchen pushen willst; aber doch bitte nicht so auf die billige Tour!

Füttere mal ein paar konkrete Fakten unter und labere nicht nur so ein allgemeines Zeugs.

[FCHennes]

@Michiko

Du glaubst doch wohl nicht, dass ein Kölner sich mit nem Schalker Namen anmeldet, oder?

Stellt sich nun die Frage, wer hier primitiv ist....

[ebbe04]

richtig!!!!!

was der hier postet ist ja nicht normal,
keine Fakten bringen aber dieses Geschwafel auf pers.Ebene.

Wenn du alles negativ siehst, dann vermeide diesen Bereich
und gehe dort hin, wo einer dein Zeug lesen will!

[malo01]

@ebbe
Du bist echt ein ..................

[malo01]

Wenn sich Michiko nicht auskennt......

[FCHennes]

So, nachdem wir nun noch mal mit günstigen Kursen eingeladen haben, ist die Talfahrt beendet.

Wir drehen gerade!!!

@Ebbe04
Guck Dir mal Axonyx ( AXYX ) an. Da kommt auch noch was.

[FCHennes]

So liebe Leute, und nachdem einige sauer waren, dass ich mal auf alte News aufmerksam gemacht habe hier nun was Brandaktuelles!!!

Und schaut euch mal an, was da grad losgeht....

DNAPrint genomics Acquires Trace Genetics of San Francisco
Tuesday June 21, 10:44 am ET
Company`s New Base of Operations on West Coast Opens Up New Markets

SARASOTA, Fla., June 21 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP - News) today announced that it has acquired Trace Genetics, Inc., of San Francisco, Calif., a provider of products and services for the genealogy, forensics, and molecular diagnostics markets. In the all- stock transaction, Trace shareholders exchanged all of the outstanding shares of Trace for 25,000,000 shares of DNAPrint common stock and options to purchase 5,000,000 additional shares at $0.02 share.

"The acquisition enables DNAPrint to establish a base of operations in the San Francisco Bay biotech corridor and broadens our sales and marketing opportunities on the West Coast," stated President and Chief Executive Officer Richard Gabriel. "By centralizing our consumer genomics and law enforcement forensics production work at Trace`s state-of-the art custom laboratory in San Francisco, we can concentrate on the acceleration of research and development at our Sarasota headquarters."

Trace ( http://www.tracegenetics.com ) brings two new complementary technologies to DNAPrint`s autosomal testing for determining the percentage of a person`s ancestry -- y-chromosome testing for tracing ancestry by following the paternal line and mitochondrial (mtDNA) x-chromosome testing for the maternal line. Trace also maintains a Native American DNA databank which, when combined with DNAPrint`s, will be one of the largest in North America. In addition, Trace maintains expertise in ancient DNA analysis from mummified and fossilized remains. DNAPrint`s proprietary human genome technology is focused on three areas: pharmacogenomics, forensics, and genealogy. All three are based on core technology for targeting single nucleotide polymorphisms (SNPs), which enables the Company to provide novel predictive genetic tests at a significant cost advantage.

Mr. Gabriel noted that Trace`s co-founders, Ripan S. Malhi, Ph.D., and Jason Eshelman, Ph.D., will join the staff of DNAPrint genomics. "We are pleased that these two talented scientists are becoming part of the DNAPrint family," Mr. Gabriel stated. "Their expertise will bring an invaluable asset to the Company at a time when we are entering a period of expansion and growth."

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company`s first theranostic product (drug/test combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.

Forward-Looking Statements

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

[luto9]

DNAPrint genomics Chairman Hector Gomez Tells Annual Meeting That Company Broadens Its Activities
6/24/05

Focusing on Three Business Segments: Pharmacogenomics, Forensics, Ancestry
Shareholders Approve Stock Combination That Allows Access to $40 Million of Growth Capital, Re-Elect Board of Directors

SARASOTA, Fla., June 24, 2005 /PRNewswire-FirstCall via COMTEX/ --
DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., told shareholders attending the Annual Meeting yesterday that "the Company`s science is the platform technology that will lead to customized medicine, which we believe is the next truly important step in identifying, treating and healing diseases. Great advances in medicine have been made by brilliant doctors and researchers at universities, hospitals and pharmaceutical companies. The mission of DNAPrint genomics and its scientist founders is to maximize these accomplishments by providing doctors a blueprint for the efficacy of various drug treatments, which may vary from person to person with the same disease because of differences in DNA.

"We have put a new face on DNAPrint," Dr. Gomez said. "DNAPrint has successfully leveraged its expertise in DNA technology into the development of pharmacogenomics, in particular, test/drug combinations called `theranostics.` In addition, we will continue to expand our line of forensic products for the law enforcement market, as well as family ancestry products for individual consumers."

Shareholders attending the Annual Meeting and those voting by proxy approved an amendment to the Company`s Articles of Incorporation to effect a stock combination of at least 1-for-10 but no more than 1-for-20 with the exact ratio to be established by the Board of Directors at the time it elects to effect the combination. The purpose for the stock combination is to be able to access up to $40 million in growth capital that has been committed to DNAPrint over the next two years so that the Company can implement its strategic plans for building both its pharmaceutical and forensics divisions. In its pharmaceutical division, DNAPrint will seek to accelerate the development of PT-401, a longer-acting and more potent compound for the anemia drug erythropoietin (EPO), to license new compounds to broaden its pharmaceutical product pipeline, and to accelerate development of its diagnostic testing products. The goal of the forensics division is to create a fully functional and certified forensics laboratory -- either through expansion of the Company`s existing facilities or through acquisition.

Dr. Gomez, in an overview of the Company`s activities, noted that DNAPrint already has a project under way to develop a new, more potent and long-acting form of the erythropoietin. Working in collaboration with Harvard Medical School`s Beth Israel Deaconess Medical Center (BIDMC), DNAPrint has begun pre- clinical work on PT-401, a "Super EPO" that would be the Company`s first Investigational New Drug (IND) once an application is filed with the U.S. Food and Drug Administration.

Dr. Gomez stated that drugs of the future will be comprised of test/drug combinations for ensuring efficacy with genetically compatible patients. "Theranostics have the potential to reduce adverse patient reactions to new drugs," he said. "Determining beforehand whether a patient will respond positively or negatively to a new drug could save them from undergoing treatments that might be ineffective, debilitating, or even life threatening."

DNAPrint Founder and Chief Scientific Officer Tony N. Frudakis, Ph.D., said that scientists and physicians have known for many years that there are inherited genetic differences across global populations and even between and among family members. "These differences are what we all celebrate as our cultural heritage," he said. "Unfortunately some of our genetic heritages often bring prevalence for disease and inabilities to metabolize medicines. Our goal is to develop a genetically based diagnostic assay protocol that enables physicians to prescribe drugs more effectively."

DNAPrint also has two other pharmacogenomic products under development. It is working with the H. Lee Moffitt Cancer Center on the development of OVANOME(TM), a test for predicting an ovarian cancer patient`s response to TAXOL/Carboplatin treatment, and STATINOME(TM), a test for predicting adverse response to cholesterol lowering medicines known as Statins. "Our DNA technology is advancing into new areas while we continue to develop our core genealogy business," Dr. Frudakis said.

DNAPrint also has a growing product line for the forensics market and recently announced that it has begun research with Penn State University on developing 3D biometric applications for the Company`s DNAWITNESS(TM) product for law enforcement. It also is completing beta trials on a DNAWITNESS test kit that enables forensics experts to conduct their own tests without sending recovered DNA back to the Company for analysis. In 2004, DNAPrint introduced RETINOME(TM), another valuable tool for forensics investigators which can determine human iris (eye) color from DNA samples.

Dr. Frudakis noted that in 2004 the Company added a new test, EURO-DNA(TM) 1.0, to complement its existing ANCESTRYbyDNA(TM) product targeting consumers who want to learn about their family heritage.

In other action, shareholders re-elected the three-member Board of Directors consisting of Dr. Gomez, Dr. Frudakis and Richard Gabriel, President and Chief Executive Officer.

Shareholders also ratified the selection of Pender, Newkirk and Company as the Company`s independent auditors for the fiscal year ending Dec. 31, 2005.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company`s first theranostic product (drug/test combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.

Forward-Looking Statements

All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Company Contact: Hector J. Gomez, M.D., Ph.D. Chairman and CMO 813-909-2029 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848

SOURCE DNAPrint genomics, Inc.

Hector J. Gomez, Chairman and CMO, DNAPrint genomics, [phone]; or Ron Stabiner of The Wall Street Group, Inc., [phone], for DNAPrint genomics http://www.prnewswire

[FCHennes]

Jeden Tag gute News!!

Da wird irgendwann was nach oben abgehen!!

Ich bleib auf jeden Fall dabei.

[brokersvenja007]

ich bin auch dabei,....wie sehr ihr die letzten beiden news?

kommt da etwas auf uns zu??

grüße
svenja

[FCHennes]

Ich denke, hier ist echt einiges möglich. Die Meldungen sind super, aber hier will man irgendwie die ganze Zeit noch günstig einsammeln. Ich denke, dass die Bodenbildung bei 0,010US-Dollar bald beendet ist und es rasant bergauf geht. DNAP hat desöfteren schon mal 100% am Tag gemacht und auf die warte ich meinetwegen noch ein paar Monate.
Die kommt!!!Verlasst euch drauf!!!

[Eristoff]

Hallo!!!!

Mit was verdienen den die, die €€€€€€€€ros??
Mit zukünftigen DNADrogentesten????

[luto9]

Technology & Science

>> Home >> Technology & Science


Humans can`t resist search for missing link


29.06.05 1.00pm


By Steve Connor


When scientists announced the completion of the Human Genome Project at a press conference in June 2000, they went out of their way to extol the unity of humankind.

We all share more than 99.9 per cent of our DNA, they said. Yet five years later the human genome is being used to identify our racial differences and geographical origins - sometimes with dubious precision.

Several companies have sprung up offering testing services that claim to be able to trace our genetic roots. In Britain they offer to identify which of seven ancient European clans we are descended from. In America they promise to find out whether a person has Jewish, African, European or native-American genes.

Oprah Winfrey, the chat-show queen, has even had a test. "I went in search of my roots," she says, "and had my DNA tested, and I am a Zulu."

Sometimes the aim of those wanting a test is to fill a void in their personal history - which can be especially painful for the descendants of the African slave trade. Others have wanted to complete a genealogical search of their family, a hunt that may have come to a dead-end using conventional paper trails.

Some Americans have even paid for DNA tests in the hope of financial gain. If they can prove they are descended from certain Native American tribes they can claim a share of profits from casinos on tribal lands.

Britain`s watchdog on genetics, the Human Genetics Commission, says some claims made in the name of "genetic genealogy" can be misleading.

"The scientific information that genealogy tests could provide might not be as precise as some of the companies suggest, and this was an area in which people should be aware of the reality of what they are being offered," the commission says.

Tracing family roots has traditionally relied on using genealogical records including certificates of births, marriages and deaths, which allow the tracing of relationships using surnames that are passed down through the male line. But the recent advances in DNA analysis have offered a new possibility of tracing our ancestors through the sequence of chemical "letters" that make up the alphabet of our genetic code.

If two living people share a similar DNA sequence, it could mean that they once shared a common ancestor.

Human DNA is stored in 46 chromosomes arranged in 23 pairs, yet just one of these chromosomes is particularly useful in tracing origins. All chromosomes except the male Y-chromosome engage in swapping, or recombination, of DNA fragments between each chromosome in the pair. This mixing produces a patchwork of ancestral DNA on a single chromosome, making it hard to decipher your ancestors based on analysing this DNA alone.

A much better tool, for men at least, is the Y-chromosome that determines maleness. Men inherit just one such chromosome from their fathers and, being on its own in the cell, it does not get involved with the messy business of recombination.

A boy`s Y-chromosome is more or less identical to that of his father, his paternal grandfather, great-grandfather and so on. The chromosome does change over time, but the process is very slow.

Analysing the genetic sequence of the Y-chromosome is therefore an excellent tool for looking at male ancestry. In fact there is now a thriving business doing just this, especially for Americans trying to trace their family roots in Europe.

Two American companies, DNAPrint Genomics, based in Sarasota, Florida, and Family Tree DNA of Houston, Texas, both offer a large selection of DNA tests that attempt to locate a person`s racial or ethnic origin or to find genetic factors shared by people with the same surnames. Both use tests based on analysing the Y-chromosomes of men.

The problem, says Professor Mark Jobling of Leicester University, who studies the genetics of the Y-chromosome, is that although such tests may indicate a degree of relatedness, they do not provide accurate information on how far back the common ancestor lived.

"Dating is limited. Saying that two men share recent patrilinear ancestors is possible, but showing when they shared that ancestor is more problematic."

Another useful tool for tracing human origins is mitochondrial DNA. This is the only DNA that occurs outside the cell nucleus, and is passed on from mothers to both their daughters and sons.

Again there is no recombination to mix up the mitochondrial DNA sequence, allowing scientists to trace ancestors back many generations. But unlike the Y-chromosome, both men and women have mitochondrial DNA, which permits ancestral tracing for both sexes.

Just as the Y-chromosome has shed light on the early evolution of men, mitochondrial DNA has revealed the origins of maternal ancestors going back many thousands of years. In fact scientists have even located a notional "mitochondrial Eve", the last common female ancestor of all humans, who lived some 200,000 years ago.

[luto9]

DNAPrint genomics Plays Key Role in Investigation of 11-Year-Old Florida Murder Case
THURSDAY, JUNE 30, 2005 7:00 AM
- PR Newswire




DNAP
0.01 n/a





Enter Symbol:



Enter Keyword:



SARASOTA, Fla., June 30, 2005 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint genomics, Inc. (DNAP) today confirmed that the Company`s forensics technology is playing a key role in an effort to solve a baffling 11-year-old murder case, thanks to the efforts of best-selling crime novelist Patricia Cornwall.

A front-page article in the Monday, June 27, edition of The Miami Herald relates how Cornwall introduced the Company`s DNA forensics technology to Hollywood, Fla., police, who had hit a stone wall in trying to find a suspect in the murder of an 85-year-old Mildred Weiss, a former legal secretary who was brutally slain in the laundry room of her apartment building in March 1994.

A decade later, author Cornwall alerted Hollywood police to new cutting- edge technology developed by DNAPrint genomics. Police investigators then sent DNA recovered from the crime scene to the Company`s laboratory for testing in May 2005. DNAPrint`s analysis determined that the killer was black, confirming what police believed to be the case based on a composite sketch drawn from the description of a man seen in the area by local residents before the murder.

The article and a companion story about the Company`s DNAWitness(TM) forensic technology also discuss the role that DNAPrint genomics has played in other high-profile murder cases. DNAPrint`s forensics technology has been used in nearly 100 law enforcement investigations since its introduction.

Both of the articles can be accessed on-line at the newspaper`s website at http://www.miami.com/mld/miamiherald/news/local/states/flori… d_county/11993639.htm and http://www.miami.com/mld/miamiherald/news/front/11993603.htm .

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests.

Forward-Looking Statements

All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Company Contact:
Hector J. Gomez, M.D., Ph.D.
Chairman and CMO
813-909-2029

-or-

[brokersvenja007]

werden die nachrichten der letzten beiden tage ausreichen, um den wert setigen zu lassen?

[FCHennes]

ES TUT SICH WAS:

BID zu 0.08 füllt sich . 550.000 Stück

Aber zu 0.08 wird keiner verkaufen!!!

Ich sach ma: DRINBLEIBEN

[FCHennes]

Achtung:

Jetzt mal kurz 300.000 aus dem ASK rausgenommen. Jetzt will wohl wirklich keiner mehr verkaufen. Grad waren noch 440.000 Stück dort. Mittlerweile nur noch 140.000......und Überhang im BID.

Kommt da gleich was?????

[FCHennes]

Sorry, sogar nur 110.000 im ASK.

[FCHennes]

Die Ruhe vor dem Sturm....

[luto9]

übertreib mal nicht, in amiland wird ganz gut verkauft.
Da wird sich wohl vor dem RS nicht mehr viel tun.

[Pushi2]

"Wünsche auch den Blinden unter Euch, dass Sie mal ein Korn finden."
"Vielleicht ernten auch die dümmsten Bauern die dicksten Kartoffeln."
Aber die "Analysen" der Frischlinge hier im Board sind nahezu unerträglich ...
Verspielt Euer Taschengeld lieber am Roulettetisch ...

[FCHennes]

@Muschi2 oder so ähnlich

Hast Du Dich verlaufen????Geh woanders spielen.

[ebbe04]

Hennes mein Kompliment!!! DER WAR ECHT GUT!
Manche wissen nicht welches Potential hier schlummert.

[Michiko]

Hennes2 lobt Hennes1 ÄCHZZ!!

[FCHennes]

Ja sicher,

ich bin Hennes, Ebbe, Muschi2 und Michiko!!!!

[FCHennes]

Sehr schön!!!

Die beste Nachricht für den richtigen Tag.
Mal sehen, ob wir heute noch über 0,20US-Cent stehen...

Tip von mir: ja

[Pushi2]

Unqualifizierter geht es wirklich nicht, Geißbock.
Beschäftige Dich mal mit den facts Deiner Empfehlungen, anstatt nur Phrasen zu dreschen ...

[FCHennes]

@Muschi2

Fakt ist: Dass du hier überflüssig bist.

Kauf dir ein paar DNAG oder geh Eier legen!

[Pushi2]

Habe mit meinen DNAP trades in den letzten Jahren schon viel Spass gehabt.
Mit volatilen Werten kann man auch gewinnen.
Natürlich nicht, wenn man auf Deinem Niveau ist.
Tschüss.
Rechne mal nach, wieviel DNAP/DNAG seit Deiner Empfehlung verloren hat ...